The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction

Phase 4

Completed

• Conditions: Acute Myocardial Infarction
• Interventions: Drug: human recombinant erythropoietin

• Registration Number: NCT00882466
• Lead Sponsor: Seoul National University Bundang Hospital

Brief Summary

The purpose of this study is to investigate the effect of intravenous human recombinant erythropoietin on the reperfusion injury at primary percutaneous coronary intervention in patients with acute myocardial infarction.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-05
• Primary Completion: 2009-02
• Study Completion: 2009-02
• Status Verified: 2009-04
• Study First Submitted: 2009-04-15
• Study First Submitted QC: 2009-04-15
• Study First Posted: 2009-04-16
• Last Update Submitted: 2009-04-16
• Last Update Posted: 2009-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

• Acute myocardial infarction <12hr
• Age >18yrs
• First myocardial infarction
• culprit lesion : proximal to mid left anterior descending artery
• Baseline coronary flow : TIMI Grade 0~1

Exclusion Criteria

• Patients with previous myocardial infarction
• History of thrombotic complication
• History of cerebral infarction
• Uncontrolled hypertension
• Increased hemoglobin level >17g/dL
• Patients with mechanical valve
• Cardiogenic shock

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EPO	human recombinant erythropoietin	-

Primary Outcome Measures

Name	Time	Method
Creatinine kinase (CK), creatinine kinase-MB (CK-MB)	4hr, 8hr, 12hr, 24hr, 48hr, 72hr

Secondary Outcome Measures

Name	Time	Method
Infarct size assessed by cardiac MRI	day 4

Trial Locations

Locations (1)

Seoul National University Bundang Hospital; 🇰🇷 Seongnam, Korea, Republic of